Our mission is delivering life-changing gene therapies to patients. Our product candidates span oncology, ophthalmology, liver diseases, respiratory disease and CNS disorders, which are all underpinned by our unique LentiVector® delivery platform. Our expertise makes us a key enabler of this new wave of medical advancement, promoting the use of lentiviral vectors for cell and gene therapies across the worldwide biopharmaceutical industry. We are developing cutting-edge science to become healthcare’s future, and of course most recently in the fight against COVID-19, through our three-year agreement with AstraZeneca for large-scale manufacturing of their COVID-19 vaccine.